C. Roemer-Bécuwe - Concepedia

Author

C. Roemer-Bécuwe

Also Known As

C Roemer-Becuwe, C. Roemer-Becuwe, C. Roemer-Bécuwe, Celia Roemer-Becuwe, Célia Roemer-Becuwe, Célia Roemer-Bécuwe, M. Rodrigues, Roemer-Becuwe, Célia

Publications

712

Citations

H-Index

Concepts

All Affiliations

Centre Léon Bérard Centre Antoine Lacassagne Centre François Baclesse Institut Bergonié Assistance Publique – Hôpitaux de Paris

About

C. Roemer-Bécuwe is an author at Centre Léon Bérard specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	390
2	Obstetrics	4	4	172
3	Public Health	2	2	95
4	Anesthesia	1	1	68
5	Immunology	1	1	44

C. Roemer-Bécuwe

Publications

575

Citations

H-Index

Page 1

	Year	Citations
Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO Isabelle Ray‐Coquard, Laure Favier, B. Weber, British Journal of Cancer	2013	102
Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial J.E. Kurtz, Anne‐Claire Hardy‐Bessard, Marion Deslandres, Gynecologic Oncology Advanced Cervical CancerCervical Cancer ManagementCervical CancerMedicineMetronomic Therapy	2009	85
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach M. Boisdron‐Celle, Olivier Capitain, Roger Faroux, Seminars in Oncology Preclinical Drug EvaluationPharmacologyToxicologyPharmacotherapyMetabolomics	2017	78
When Midazolam Fails Christine M. Cheng, C. Roemer-Bécuwe, José Pereira Journal of Pain and Symptom Management Heart FailureMidazolam FailsPatient SafetyNeuropharmacologyPharmacovigilance	2002	68
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group Pierre-Étienne Heudel, Michel Fabbro, C. Roemer-Bécuwe, British Journal of Cancer	2017	64
Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study F. Joly, Djihane Ahmed-Lecheheb, Elsa Kalbacher, Annals of Oncology Long-term FatigueLife AssessmentMedicineCancer ManagementGynecology	2019	50
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer Giuseppe Curigliano, Gilles Romieu, Mario Campone, Breast Cancer Research and Treatment Breast OncologyMedicineImmunologyImmune Checkpoint InhibitorBreast Cancer	2016	44
Safety of subcutaneous clodronate and efficacy in hypercalcemia of malignancy: a novel route of administration C. Roemer-Bécuwe, Antonio Viganò, Fabrizio Romano, Journal of Pain and Symptom Management MedicineNovel RouteSubcutaneous ClodronateMetabolic Bone DiseasePharmacology	2003	28
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial Roberto Sorio, C. Roemer-Bécuwe, Felix Hilpert, Gynecologic Oncology OncologyElderly PatientsMetronomic TherapyClinical TrialsGynecology	2016	27
Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer Lidia Delrieu, Emmanuelle Jacquet, Céline Ségura‐Ferlay, Scientific Reports	2020	19

Page 1